Acute transaminitis as an atypical presentation of Graft-versus-Host Disease following Hematopoietic Stem Cell Transplantation

Abstract

Graft versus Host Disease (GVHD) can present with mucocutaneous, gastrointestinal and hepatic manifestations, specifically a cholestatic transaminitis. Rarely, some cases can present with only a hepatocellular transaminitis. Our patient presented with an acute hepatitis on day +90 post-hematopoietic stem cell transplant, without other overt manifestations of GVHD. The initial work up was negative for a viral etiology or causative drug, and the patient’s transaminases continued to rise. On day +96, an erythematous rash appeared with biopsy indicating lymphocytic and eosinophilic infiltrates concerning for cutaneous GVHD. Subsequently, a liver biopsy was obtained, and showed marked ductopenia with cholestasis, consistent with hepatic GVHD.

Keywords

Transaminitis / Hepatitis / Graft-versus-Host Disease / Hematopoietic Stem Cell Transplant

CONFLICTS OF INTEREST DISCLOSURE

The authors declare that they have no competing interest.

References

[1] McDonald GB, Shulman HM, Wolford JL, et al. Liver disease after human marrow transplantation. Seminars in Liver Disease. 1987; 7: 210-29. PMid:3317859. https://doi.org/10.1055/s-2008-1040578

[2] Shulman HM, Kleiner D, Lee SJ, et al. Histopathologic Diagnosis of Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biology of Blood and Marrow Transplantation. 2006; 12: 31-47. https://doi.org/10.1016/j.bbmt.2005.10.023

[3] Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Practice & Research: Clinical Hematology. 2008; 21(2): 101-17. https://doi.org/10.1016/j.beha.2008.02.005

[4] Ferrara JL, Yanik G. Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies. Clinical Advances in Hematology & Oncology. 2005; 3(5): 415-9. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16167015

[5] Atkinson K. Chronic graft-versus-host disease. Bone Marrow Transplant. 1990; 5(2): 69-82. Available from: https://www.ncbi.nlm.nih.gov/pubmed/2178709

[6] Crawford JM. Graft-versus-Host Disease (2nd ed.). New York, NY: Marcel Dekker; 1997.

[7] Ferrara JL, Deeg HJ. Graft-versus-host disease. New England Journal of Medicine. 1991; 324(10): 667-74. PMid:1994250. https://doi.org/10.1056/NEJM199103073241005

[8] Yasmineh WG, Filipovich AH, Killeen AA. Serum 5’nucleotidase and alkaline phosphatase - highly predictive liver function tests for the diagnosis of graft-versus-host disease in bone marrow transplantation recipients. Transplantation. 1989; 48: 809-14. PMid:2554545. https://doi.org/10.1097/00007890-198911000-00017

[9] Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. Journal of Hepatology. 2001; 35: 134-46. https://doi.org/10.1016/S0168-8278(01)00092-7

[10] Jacobsohn DA, Montross S, Anders V, et al. Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease. Bone Marrow Transplant. 2001; 28: 1047-51. PMid:11781615. https://doi.org/10.1038/sj.bmt.1703278

[11] Fujii N, Takenaka K, Shinagawa K, et al. Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant. 2001; 27: 1007-10. PMid:11436113. https://doi.org/10.1038/sj.bmt.1702997

[12] Malik AH, Collins RH, Saboorian MH, et al. Chronic graft versushost disease after hematopoietic cell transplantation presenting as an acute hepatitis. American Journal of Gastroenterology. 2001; 96: 588-90 PMid:11232714. https://doi.org/10.1111/j.1572-0241.2001.03563.x

[13] Strasser SI, Shulman HM, Flowers ME, et al. Chronic graft-versus host disease of the liver: presentation as an acute hepatitis. Hepatology. 2000; 32: 1265-71. PMid:11093733. https://doi.org/10.1053/jhep.2000.20067

[14] Silverman LB, Stevenson KE, O’Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia 1985-2000. Leukemia. 2010; 24(2): 320-334. PMid:20016537. https://doi.org/10.1038/leu.2009.253

[15] Maeng H, Lee JH, Cheong JW, et al. Chronic Graft-versus-Host Disease of the Liver Presenting as an Acute Hepatitis following Non-myeloablative Hematopoietic Stem Cell Transplantation. International Journal of Hematology. 2004; 79: 501-4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15239404

[16] Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood. 2003; 102(2): 756-62. PMid:12663454. https://doi.org/10.1182/blood-2002-08-2628

[17] Chen MH, Chiou TJ, Lin PC, et al. Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia. International Journal of Hematology. 2007; 86(3): 275-81. https://doi.org/10.1007/BF03006933